Adoptive cell transfer (ACT)—including CAR T cells—has achieved remarkable success against some cancers, especially blood cancers. However, sometimes these T cells become inactivated prematurely. Dr. Villadangos found that this can happen is if the density of tumor cells is too high. He termed this phenomenon “stunning” and now he is determining what causes it. He’s also characterizing the broader relationship between tumor and immune cells and determining how they influence anti-cancer immune responses. Overall, Dr. Villadangos’ work will hopefully suggest ways to address stunning and augment current ACT approaches.
The University of Melbourne (Australia) | All Cancers | 2016
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Cell therapy development lagged in 2020, but is gaining ground again, a new CRI report shows.
CRI scientists will highlight cancer immunotherapy advances in the clinic at the 2021 ASCO annual meeting.